15 results on '"Gazaryan I"'
Search Results
2. Biosensors based on novel peroxidases with improved properties in direct and mediated electron transfer
- Author
-
Lindgren, A., Ruzgas, T., Gorton, L., Csoregi, E., Ardila, G. Bautista, Sakharov, I. Y., and Gazaryan, I. G.
- Published
- 2000
- Full Text
- View/download PDF
3. A critical appraisal of ferroptosis in Alzheimer's and Parkinson's disease: new insights into emerging mechanisms and therapeutic targets.
- Author
-
Soni P, Ammal Kaidery N, Sharma SM, Gazaryan I, Nikulin SV, Hushpulian DM, and Thomas B
- Abstract
Neurodegenerative diseases represent a pressing global health challenge, and the identification of novel mechanisms underlying their pathogenesis is of utmost importance. Ferroptosis, a non-apoptotic form of regulated cell death characterized by iron-dependent lipid peroxidation, has emerged as a pivotal player in the pathogenesis of neurodegenerative diseases. This review delves into the discovery of ferroptosis, the critical players involved, and their intricate role in the underlying mechanisms of neurodegeneration, with an emphasis on Alzheimer's and Parkinson's diseases. We critically appraise unsolved mechanistic links involved in the initiation and propagation of ferroptosis, such as a signaling cascade resulting in the de-repression of lipoxygenase translation and the role played by mitochondrial voltage-dependent anionic channels in iron homeostasis. Particular attention is given to the dual role of heme oxygenase in ferroptosis, which may be linked to the non-specific activity of P450 reductase in the endoplasmic reticulum. Despite the limited knowledge of ferroptosis initiation and progression in neurodegeneration, Nrf2/Bach1 target genes have emerged as crucial defenders in anti-ferroptotic pathways. The activation of Nrf2 and the inhibition of Bach1 can counteract ferroptosis and present a promising avenue for future therapeutic interventions targeting ferroptosis in neurodegenerative diseases., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Soni, Ammal Kaidery, Sharma, Gazaryan, Nikulin, Hushpulian and Thomas.)
- Published
- 2024
- Full Text
- View/download PDF
4. Harnessing the Therapeutic Potential of the Nrf2/Bach1 Signaling Pathway in Parkinson's Disease.
- Author
-
Ahuja M, Kaidery NA, Dutta D, Attucks OC, Kazakov EH, Gazaryan I, Matsumoto M, Igarashi K, Sharma SM, and Thomas B
- Abstract
Parkinson's disease (PD) is the second most common neurodegenerative movement disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Although a complex interplay of multiple environmental and genetic factors has been implicated, the etiology of neuronal death in PD remains unresolved. Various mechanisms of neuronal degeneration in PD have been proposed, including oxidative stress, mitochondrial dysfunction, neuroinflammation, α-synuclein proteostasis, disruption of calcium homeostasis, and other cell death pathways. While many drugs individually targeting these pathways have shown promise in preclinical PD models, this promise has not yet translated into neuroprotective therapies in human PD. This has consequently spurred efforts to identify alternative targets with multipronged therapeutic approaches. A promising therapeutic target that could modulate multiple etiological pathways involves drug-induced activation of a coordinated genetic program regulated by the transcription factor, nuclear factor E2-related factor 2 (Nrf2). Nrf2 regulates the transcription of over 250 genes, creating a multifaceted network that integrates cellular activities by expressing cytoprotective genes, promoting the resolution of inflammation, restoring redox and protein homeostasis, stimulating energy metabolism, and facilitating repair. However, FDA-approved electrophilic Nrf2 activators cause irreversible alkylation of cysteine residues in various cellular proteins resulting in side effects. We propose that the transcriptional repressor of BTB and CNC homology 1 (Bach1), which antagonizes Nrf2, could serve as a promising complementary target for the activation of both Nrf2-dependent and Nrf2-independent neuroprotective pathways. This review presents the current knowledge on the Nrf2/Bach1 signaling pathway, its role in various cellular processes, and the benefits of simultaneously inhibiting Bach1 and stabilizing Nrf2 using non-electrophilic small molecules as a novel therapeutic approach for PD.
- Published
- 2022
- Full Text
- View/download PDF
5. Probable Mechanisms of Doxorubicin Antitumor Activity Enhancement by Ginsenoside Rh2.
- Author
-
Popov A, Klimovich A, Styshova O, Tsybulsky A, Hushpulian D, Osipyants A, Khristichenko A, Kazakov S, Ahuja M, Kaidery N, Thomas B, Tishkov V, Brown A, Gazaryan I, and Poloznikov A
- Subjects
- Animals, Doxorubicin pharmacology, Mice, Adenocarcinoma, Drugs, Chinese Herbal pharmacology, Ginsenosides pharmacology
- Abstract
Ginsenoside Rh2 increases the efficacy of doxorubicin (DOX) treatment in murine models of solid and ascites Ehrlich's adenocarcinoma. In a solid tumor model (treatment commencing 7 days after inoculation), DOX + Rh2 co-treatment was significantly more efficacious than DOX alone. If treatment was started 24 h after inoculation, the inhibition of tumor growth of a solid tumor for the DOX + Rh2 co-treatment group was complete. Furthermore, survival in the ascites model was dramatically higher for the DOX + Rh2 co-treatment group than for DOX alone. Mechanisms underlying the combined DOX and Rh2 effects were studied in primary Ehrlich's adenocarcinoma-derived cells and healthy mice's splenocytes. Despite the previously established Rh2 pro-oxidant activity, DOX + Rh2 co-treatment revealed no increase in ROS compared to DOX treatment alone. However, DOX + Rh2 treatment was more effective in suppressing Ehrlich adenocarcinoma cell adhesion than either treatment alone. We hypothesize that the benefits of DOX + Rh2 combination treatment are due to the suppression of tumor cell attachment/invasion that might be effective in preventing metastatic spread of tumor cells. Ginsenoside Rh2 was found to be a modest activator in a Neh2-luc reporter assay, suggesting that Rh2 can activate the Nrf2-driven antioxidant program. Rh2-induced direct activation of Nrf2 might provide additional benefits by minimizing DOX toxicity towards non-cancerous cells.
- Published
- 2022
- Full Text
- View/download PDF
6. Bach1 derepression is neuroprotective in a mouse model of Parkinson's disease.
- Author
-
Ahuja M, Ammal Kaidery N, Attucks OC, McDade E, Hushpulian DM, Gaisin A, Gaisina I, Ahn YH, Nikulin S, Poloznikov A, Gazaryan I, Yamamoto M, Matsumoto M, Igarashi K, Sharma SM, and Thomas B
- Subjects
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Aged, Aged, 80 and over, Animals, Antioxidant Response Elements, Basic-Leucine Zipper Transcription Factors antagonists & inhibitors, Basic-Leucine Zipper Transcription Factors genetics, Case-Control Studies, Disease Models, Animal, Drug Evaluation, Preclinical, Female, Humans, Male, Mice, Mice, Knockout, Parkinson Disease metabolism, Rats, Basic-Leucine Zipper Transcription Factors metabolism, Neuroprotection, Parkinson Disease therapy
- Abstract
Parkinson's disease (PD) is a progressive neurodegenerative movement disorder characterized by the loss of nigrostriatal dopaminergic neurons. Mounting evidence suggests that Nrf2 is a promising target for neuroprotective interventions in PD. However, electrophilic chemical properties of the canonical Nrf2-based drugs cause irreversible alkylation of cysteine residues on cellular proteins resulting in side effects. Bach1 is a known transcriptional repressor of the Nrf2 pathway. We report that Bach1 levels are up-regulated in PD postmortem brains and preclinical models. Bach1 knockout (KO) mice were protected against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity and associated oxidative damage and neuroinflammation. Functional genomic analysis demonstrated that the neuroprotective effects in Bach1 KO mice was due to up-regulation of Bach1-targeted pathways that are associated with both Nrf2-dependent antioxidant response element (ARE) and Nrf2-independent non-ARE genes. Using a proprietary translational technology platform, a drug library screen identified a substituted benzimidazole as a Bach1 inhibitor that was validated as a nonelectrophile. Oral administration of the Bach1 inhibitor attenuated MPTP neurotoxicity in pre- and posttreatment paradigms. Bach1 inhibitor-induced neuroprotection was associated with the up-regulation of Bach1-targeted pathways in concurrence with the results from Bach1 KO mice. Our results suggest that genetic deletion as well as pharmacologic inhibition of Bach1 by a nonelectrophilic inhibitor is a promising therapeutic approach for PD., Competing Interests: The authors declare no competing interest., (Copyright © 2021 the Author(s). Published by PNAS.)
- Published
- 2021
- Full Text
- View/download PDF
7. Non-canonical Keap1-independent activation of Nrf2 in astrocytes by mild oxidative stress.
- Author
-
Al-Mubarak BR, Bell KFS, Chowdhry S, Meakin PJ, Baxter PS, McKay S, Dando O, Ashford MLJ, Gazaryan I, Hayes JD, and Hardingham GE
- Subjects
- Animals, Antioxidants, Kelch-Like ECH-Associated Protein 1 genetics, Mice, NF-E2-Related Factor 2 genetics, Oxidative Stress, Astrocytes metabolism, Kelch-Like ECH-Associated Protein 1 metabolism, NF-E2-Related Factor 2 metabolism
- Abstract
The transcription factor Nrf2 is a stress-responsive master regulator of antioxidant, detoxification and proteostasis genes. In astrocytes, Nrf2-dependent gene expression drives cell-autonomous cytoprotection and also non-cell-autonomous protection of nearby neurons, and can ameliorate pathology in several acute and chronic neurological disorders associated with oxidative stress. However, the value of astrocytic Nrf2 as a therapeutic target depends in part on whether Nrf2 activation by disease-associated oxidative stress occludes the effect of any Nrf2-activating drug. Nrf2 activation classically involves the inhibition of interactions between Nrf2's Neh2 domain and Keap1, which directs Nrf2 degradation. Keap1 inhibition is mediated by the modification of cysteine residues on Keap1, and can be triggered by electrophilic small molecules such as tBHQ. Here we show that astrocytic Nrf2 activation by oxidative stress involves Keap1-independent non-canonical signaling. Keap1 deficiency elevates basal Nrf2 target gene expression in astrocytes and occludes the effects of tBHQ, oxidative stress still induced strong Nrf2-dependent gene expression in Keap1-deficient astrocytes. Moreover, while tBHQ prevented protein degradation mediated via Nrf2's Neh2 domain, oxidative stress did not, consistent with a Keap1-independent mechanism. Moreover the effects of oxidative stress and tBHQ on Nrf2 target gene expression are additive, not occlusive. Mechanistically, oxidative stress enhances the transactivation potential of Nrf2's Neh5 domain in a manner dependent on its Cys-191 residue. Thus, astrocytic Nrf2 activation by oxidative stress involves Keap1-independent non-canonical signaling, meaning that further Nrf2 activation by Keap1-inhibiting drugs may be a viable therapeutic strategy., (Copyright © 2021. Published by Elsevier B.V.)
- Published
- 2021
- Full Text
- View/download PDF
8. HIF1α stabilization in hypoxia is not oxidant-initiated.
- Author
-
Kumar A, Vaish M, Karuppagounder SS, Gazaryan I, Cave JW, Starkov AA, Anderson ET, Zhang S, Pinto JT, Rountree AM, Wang W, Sweet IR, and Ratan RR
- Subjects
- Animals, HeLa Cells, Humans, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, Male, Mice, Mitochondria metabolism, Protein Stability, Rats, Rats, Sprague-Dawley, Signal Transduction, Cell Hypoxia, Hypoxia-Inducible Factor 1, alpha Subunit genetics, Peroxides metabolism
- Abstract
Hypoxic adaptation mediated by HIF transcription factors requires mitochondria, which have been implicated in regulating HIF1α stability in hypoxia by distinct models that involve consuming oxygen or alternatively converting oxygen into the second messenger peroxide. Here, we use a ratiometric, peroxide reporter, HyPer to evaluate the role of peroxide in regulating HIF1α stability. We show that antioxidant enzymes are neither homeostatically induced nor are peroxide levels increased in hypoxia. Additionally, forced expression of diverse antioxidant enzymes, all of which diminish peroxide, had disparate effects on HIF1α protein stability. Moreover, decrease in lipid peroxides by glutathione peroxidase-4 or superoxide by mitochondrial SOD, failed to influence HIF1α protein stability. These data show that mitochondrial, cytosolic or lipid ROS were not necessary for HIF1α stability, and favor a model where mitochondria contribute to hypoxic adaptation as oxygen consumers., Competing Interests: AK, MV, SK, IG, JC, AS, EA, SZ, JP, AR, WW, IS, RR No competing interests declared, (© 2021, Kumar et al.)
- Published
- 2021
- Full Text
- View/download PDF
9. Neuroprotective Effect of HIF Prolyl Hydroxylase Inhibition in an In Vitro Hypoxia Model.
- Author
-
Savyuk M, Krivonosov M, Mishchenko T, Gazaryan I, Ivanchenko M, Khristichenko A, Poloznikov A, Hushpulian D, Nikulin S, Tonevitsky E, Abuzarova G, Mitroshina E, and Vedunova M
- Abstract
A novel potent analog of the branched tail oxyquinoline group of hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors, neuradapt, has been studied in two treatment regimes in an in vitro hypoxia model on murine primary hippocampal cultures. Neuradapt activates the expression of HIF1 and HIF2 target genes and shows no toxicity up to 20 μM, which is more than an order of magnitude higher than its biologically active concentration. Cell viability, functional activity, and network connectivity between the elements of neuronal networks have been studied using a pairwise correlation analysis of the intracellular calcium fluctuations in the individual cells. An immediate treatment with 1 μМ and 15 μМ neuradapt right at the onset of hypoxia not only protects from the death, but also maintains the spontaneous calcium activity in nervous cells at the level of the intact cultures. A similar neuroprotective effect in the post-treatment scenario is observed for 15 μМ, but not for 1 μМ neuradapt. Network connectivity is better preserved with immediate treatment using 1 μМ neuradapt than with 15 μМ, which is still beneficial. Post-treatment with neuradapt did not restore the network connectivity despite the observation that neuradapt significantly increased cell viability at 1 μМ and functional activity at 15 μМ. The preservation of cell viability and functional activity makes neuradapt promising for further studies in a post-treatment scenario, since it can be combined with other drugs and treatments restoring the network connectivity of functionally competent cells., Competing Interests: The authors declare no conflict of interest.
- Published
- 2020
- Full Text
- View/download PDF
10. In vitro and in silico liver models: Current trends, challenges and opportunities.
- Author
-
Poloznikov A, Gazaryan I, Shkurnikov M, Nikulin S, Drapkina O, Baranova A, and Tonevitsky A
- Subjects
- Animals, Cell Culture Techniques, Chemical and Drug Induced Liver Injury prevention & control, Drug Discovery trends, Hepatocytes drug effects, Humans, Cells, Cultured drug effects, Computer Simulation trends, In Vitro Techniques trends, Liver drug effects
- Abstract
Most common drug development failures originate from either bioavailability problems, or unexpected toxic effects. The culprit is often the liver, which is responsible for biotransformation of a majority of xenobiotics. Liver may be modeled using "liver on a chip" devices, which may include established cell lines, primary human cells, and stem cell-derived hepatocyte-like cells. The choice of biological material along with its processing and maintenance greatly influence both the device performance and the resultant toxicity predictions. Impediments to the development of "liver on a chip" technology include the problems with standardization of cells, limitations imposed by culturing and the necessity to develop more complicated fluidic contours. Fortunately, recent breakthroughs in the development of cell-based reporters, including ones with fluorescent label, permits monitoring of the behavior of the cells embed into the "liver on a chip" devices. Finally, a set of computational approaches has been developed to model both particular toxic response and the homeostasis of human liver as a whole; these approaches pave a way to enhance the in silico stage of assessment for a potential toxicity.
- Published
- 2018
- Full Text
- View/download PDF
11. Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease.
- Author
-
Ahuja M, Ammal Kaidery N, Yang L, Calingasan N, Smirnova N, Gaisin A, Gaisina IN, Gazaryan I, Hushpulian DM, Kaddour-Djebbar I, Bollag WB, Morgan JC, Ratan RR, Starkov AA, Beal MF, and Thomas B
- Subjects
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine pharmacology, Animals, Antigens, CD metabolism, Cell Line, Transformed, Disease Models, Animal, Dose-Response Relationship, Drug, Fumarates pharmacology, Gene Expression Regulation drug effects, Gene Expression Regulation genetics, Humans, Maleates pharmacology, Mice, Mice, Inbred C57BL, Mice, Knockout, NF-E2-Related Factor 2 genetics, Parkinsonian Disorders prevention & control, Rats, Tyrosine analogs & derivatives, Tyrosine pharmacology, Fumarates therapeutic use, NF-E2-Related Factor 2 metabolism, Neuroprotective Agents therapeutic use, Parkinsonian Disorders chemically induced, Parkinsonian Disorders drug therapy, Signal Transduction drug effects
- Abstract
Unlabelled: A promising approach to neurotherapeutics involves activating the nuclear-factor-E2-related factor 2 (Nrf2)/antioxidant response element signaling, which regulates expression of antioxidant, anti-inflammatory, and cytoprotective genes. Tecfidera, a putative Nrf2 activator, is an oral formulation of dimethylfumarate (DMF) used to treat multiple sclerosis. We compared the effects of DMF and its bioactive metabolite monomethylfumarate (MMF) on Nrf2 signaling and their ability to block 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced experimental Parkinson's disease (PD). We show that in vitro DMF and MMF activate the Nrf2 pathway via S-alkylation of the Nrf2 inhibitor Keap1 and by causing nuclear exit of the Nrf2 repressor Bach1. Nrf2 activation by DMF but not MMF was associated with depletion of glutathione, decreased cell viability, and inhibition of mitochondrial oxygen consumption and glycolysis rates in a dose-dependent manner, whereas MMF increased these activities in vitro However, both DMF and MMF upregulated mitochondrial biogenesis in vitro in an Nrf2-dependent manner. Despite the in vitro differences, both DMF and MMF exerted similar neuroprotective effects and blocked MPTP neurotoxicity in wild-type but not in Nrf2 null mice. Our data suggest that DMF and MMF exhibit neuroprotective effects against MPTP neurotoxicity because of their distinct Nrf2-mediated antioxidant, anti-inflammatory, and mitochondrial functional/biogenetic effects, but MMF does so without depleting glutathione and inhibiting mitochondrial and glycolytic functions. Given that oxidative damage, neuroinflammation, and mitochondrial dysfunction are all implicated in PD pathogenesis, our results provide preclinical evidence for the development of MMF rather than DMF as a novel PD therapeutic., Significance Statement: Almost two centuries since its first description by James Parkinson, Parkinson's disease (PD) remains an incurable disease with limited symptomatic treatment. The current study provides preclinical evidence that a Food and Drug Administration-approved drug, dimethylfumarate (DMF), and its metabolite monomethylfumarate (MMF) can block nigrostriatal dopaminergic neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of PD. We elucidated mechanisms by which DMF and its active metabolite MMF activates the redox-sensitive transcription factor nuclear-factor-E2-related factor 2 (Nrf2) to upregulate antioxidant, anti-inflammatory, mitochondrial biosynthetic and cytoprotective genes to render neuroprotection via distinct S-alkylating properties and depletion of glutathione. Our data suggest that targeting Nrf2-mediated gene transcription using MMF rather than DMF is a promising approach to block oxidative stress, neuroinflammation, and mitochondrial dysfunction for therapeutic intervention in PD while minimizing side effects., (Copyright © 2016 the authors 0270-6474/16/366333-20$15.00/0.)
- Published
- 2016
- Full Text
- View/download PDF
12. Physicochemical characterization of natural ionic Microreservoirs: Bacillus subtilis dormant spores.
- Author
-
Kazakov S, Bonvouloir E, and Gazaryan I
- Subjects
- Cell Membrane metabolism, Chemistry, Physical methods, Ions, Kinetics, Microchemistry, Bacillus subtilis cytology, Cell Membrane Permeability, Potentiometry, Protons, Spores, Bacterial metabolism
- Abstract
The kinetics of proton exchange between dormant spores and aqueous environment was examined by time-resolved micropotentiometry, the method we recently introduced for hydrogel particles of micro- and nanometer diameter (J. Phys. Chem. B 2006, 110, 15107). In this work, the method was applied to the suspensions of dormant Bacillus subtilis spore of different concentrations to show that proton uptake kinetics was a multistep process involving a number of successively approximately 10-fold slower steps of proton penetration into the bulk and their binding to the ionizable groups within different layers of a spore structure. By analyzing the proton equilibrium binding to ionizable groups inside a spore, it was shown that each Bacillus subtilis spore behaves like almost infinite ionic reservoir capable of accumulating billions of protons (N approximately 2 x 10(10) per spore). The obtained pK(a) value of 4.7 for the spores studied is the first quantitative indication on carboxyl groups as the major ionizable groups fixed in a spore matrix. In general, proton equilibrium binding within the spore matrix obeys the fundamental law of the Langmuir isotherm. The proton binding to the ionizable groups slows down the free proton diffusion within a spore, but this effect is substantially weakened by increasing the initial concentration of protons added. On the basis of the diffusion time analysis, it was found that the effective diffusion coefficient for hydrogen ions within the spore core can be up to 3 orders of magnitude lower than that within the coats and cortex. We speculate that the spore inner membrane which separates core from cortex and coats in a dormant spore is a major permeability barrier for protons to penetrate into a lockbox of the genetic information (core).
- Published
- 2008
- Full Text
- View/download PDF
13. Harnessing hypoxic adaptation to prevent, treat, and repair stroke.
- Author
-
Ratan RR, Siddiq A, Smirnova N, Karpisheva K, Haskew-Layton R, McConoughey S, Langley B, Estevez A, Huerta PT, Volpe B, Roy S, Sen CK, Gazaryan I, Cho S, Fink M, and LaManna J
- Subjects
- Adaptation, Physiological, Animals, Brain metabolism, Brain pathology, Brain physiopathology, Enzyme Inhibitors therapeutic use, Humans, Hypoxia, Brain metabolism, Hypoxia, Brain pathology, Hypoxia, Brain physiopathology, Hypoxia-Inducible Factor 1 metabolism, Neuroprotective Agents therapeutic use, Oxidative Stress drug effects, Procollagen-Proline Dioxygenase antagonists & inhibitors, Procollagen-Proline Dioxygenase metabolism, Signal Transduction drug effects, Stroke metabolism, Stroke pathology, Stroke physiopathology, Brain drug effects, Enzyme Inhibitors pharmacology, Hypoxia, Brain drug therapy, Neuroprotective Agents pharmacology, Oxygen metabolism, Stroke drug therapy
- Abstract
The brain demands oxygen and glucose to fulfill its roles as the master regulator of body functions as diverse as bladder control and creative thinking. Chemical and electrical transmission in the nervous system is rapidly disrupted in stroke as a result of hypoxia and hypoglycemia. Despite being highly evolved in its architecture, the human brain appears to utilize phylogenetically conserved homeostatic strategies to combat hypoxia and ischemia. Specifically, several converging lines of inquiry have demonstrated that the transcription factor hypoxia-inducible factor-1 (HIF1-1) mediates the activation of a large cassette of genes involved in adaptation to hypoxia in surviving neurons after stroke. Accordingly, pharmacological or molecular approaches that engage hypoxic adaptation at the point of one of its sensors (e.g., inhibition of HIF prolyl 4 hydroxylases) leads to profound sparing of brain tissue and enhanced recovery of function. In this review, we discuss the potential mechanisms that could subserve protective and restorative effects of augmenting hypoxic adaptation in the brain. The strategy appears to involve HIF-dependent and HIF-independent pathways and more than 70 genes and proteins activated transcriptionally and post-transcriptionally that can act at cellular, local, and system levels to compensate for oxygen insufficiency. The breadth and depth of this homeostatic program offers a hopeful alternative to the current pessimism towards stroke therapeutics.
- Published
- 2007
- Full Text
- View/download PDF
14. Ion concentration of external solution as a characteristic of micro- and nanogel ionic reservoirs.
- Author
-
Kazakov S, Kaholek M, Gazaryan I, Krasnikov B, Miller K, and Levon K
- Subjects
- Hydrogen-Ion Concentration, Ions chemistry, Kinetics, Models, Chemical, Osmolar Concentration, Particle Size, Polyvinyls, Sensitivity and Specificity, Solutions chemistry, Time Factors, Hydrogels chemistry, Imidazoles chemistry, Vinyl Compounds chemistry
- Abstract
Ion-sensitive hydrogel is regarded as an ionic reservoir, i.e., a system capable of changing the external pH or ionic strength by accumulating or releasing ions. The concept of a hydrogel ionic reservoir was demonstrated for hydrogel particles of three different size ranges: macrogel (1000-6000 microm), microgel (approximately 20-200 microm), and nanogel (approximately 0.2 microm). Ion sensitivity of poly(N-isopropylacrylamide-co-1-vinylimidazole) (PNIPA-VI) microgels with imidazolyl (ionizable) groups was confirmed by the pH dependence of their volume, while nanogels were characterized by dynamic light scattering. On the contrary, the volume of poly(N-isopropylacrylamide) (PNIPA) microgels without ionizable groups was pH independent in the whole range of pH from 10 to 2. Four distinct regions of pH-behavior were observed for PNIPA-VI hydrogel micro- and nanoparticles using potentiometric titration of their suspensions. Time-resolved measurements of ion concentrations in the suspension of hydrogel particles revealed a substantial difference in kinetics of pH equilibration for (i) ion-sensitive hydrogels (PNIPA-VI) vs hydrogels without ionizable groups (PNIPA) and (ii) PNIPA-VI hydrogels of different sizes. On the basis of the experimental observations, a two-step mechanism affecting the kinetics of proton uptake into the hydrogel particles with ionizable groups was proposed: (1) fast binding of ions to the immediate surface of each particle and (2) a slower successive diffusion of bound sites into the next inner layer of polymer network. In accord with the mechanism proposed, a quasi-chemical kinetic model of pH relaxation to equilibrium was developed to fit the experimental data for the time course of proton uptake by macro-, micro-, and nanogels into two exponentials with the characteristic times of tau(1) and tau(2). We believe the same kinetic model will be pertinent to describe phenomenological and molecular mechanisms controlling proton transport in/out bacteria, cells, organelles, drug delivery vehicles, and other natural or artificial multifunctional ionic containers. The approach can be easily extended for the other ions (e.g., Na(+), K(+), and Ca(2+)).
- Published
- 2006
- Full Text
- View/download PDF
15. Effect of single-point mutations Phe41-->His and Phe143-->Glu on folding and catalytic properties of recombinant horseradish peroxidase expressed in E. coli.
- Author
-
Gazaryan IG, Doseeva VV, Galkin AG, and Tishkov VI
- Subjects
- Base Sequence, Binding Sites, Catalysis, Escherichia coli genetics, Heme metabolism, Horseradish Peroxidase genetics, Hydrogen Peroxide metabolism, Kinetics, Molecular Sequence Data, Mutagenesis, Site-Directed, Protein Folding, Recombinant Proteins chemistry, Recombinant Proteins metabolism, Structure-Activity Relationship, Glutamic Acid genetics, Histidine genetics, Horseradish Peroxidase chemistry, Horseradish Peroxidase metabolism, Phenylalanine genetics, Point Mutation
- Abstract
Wild-type recombinant and Phe41-->His and Phe143-->Glu mutant forms of horseradish peroxidase have been expressed in E. coli and reactivated from inclusion bodies with a yield of about 25%. The purified homogeneous preparations have been studied in the reaction of ABTS oxidation. The effect of mutations on heme entrapment and kinetics of ABTS oxidation demonstrates the essential role of the replaced residues in providing the hydrophobic crevice for the non-covalent heme binding.
- Published
- 1994
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.